Shattuck Labs Inc stock is traded at $4.61, with a volume of 814,764. It is up +3.13% in the last 24 hours and down -14.15% over the past month. Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
Previous Close:
$4.47
Open:
$4.48
24h Volume:
814,764
Relative Volume:
0.69
Market Cap:
$469.49M
Revenue:
$1.00M
Net Income/Loss:
-$48.81M
P/E Ratio:
-
EPS:
-$0.7737
Net Cash Flow:
-$39.95M
1W Performance:
-4.16%
1M Performance:
-14.15%
6M Performance:
-20.38%
1Y Performance:
+135.20%
1-Day Range:
$4.43$4.65
1-Week Range:
$4.34$4.83
52-Week Range:
$1.88$8.33
Shattuck Labs Inc Stock (STTK) Company Profile
Name
Shattuck Labs IncSector
HealthcareIndustry
BiotechnologyPhone
512-900-4690Address
500 W. 5TH STREET, AUSTIN, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS